心力衰竭患者的利尿治疗:当前的证据和未来的方向 - - 第一部分:循环利尿剂
Joseph James Cuthbert1,2, Andrew L Clark3
1Clinical Sciences Centre, Hull York Medical School, University of Hull, Cottingham Road, Kingston-Upon-Hull, East Yorkshire, UK. Joe.cuthbert@hyms.ac.uk.
Current heart failure reports
|January 19, 2024
概括
循环利尿剂仍然是心力衰竭 (HF) 拥堵的主要治疗方法,尽管证据有限. 最近的试验强调了需要更好的利尿剂策略和更多的研究,以改善患者在高温管理中的结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 流体保留是心力衰竭 (HF) 患者症状和生活质量差的主要原因.
- 循环利尿剂是控制高血压拥堵的主要支柱,50年来治疗策略几乎没有变化.
研究的目的:
- 审查心力衰竭中利尿剂治疗策略的历史和当前证据.
- 探索潜在的未来研究方向,以优化HF的利尿疗法.
主要方法:
- 对最近的临床试验进行评估,包括DOSE,TRANSFORM,ADVOR,CLOROTIC,OSPREY-AHF和PUSH-AHF等.
- 评估试验证据如何影响当前的临床实践和HF管理的未来研究.
主要成果:
- 强有力的证据支持高剂量循环利尿剂治疗,而不是低剂量治疗住院HF患者,尽管这并不总是反映在指南中.
- 在常规的临床实践中,大量缺乏数据来指导利尿剂治疗决策.
结论:
- 目前用于心力衰竭的利尿剂策略没有得到充分的临床证据支持.
- 迫切需要对各种利尿剂策略进行更全面的研究,以改善HF患者的护理和结果.
相关概念视频
Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Antihypertensive Drugs: Potassium-Sparing Diuretics
563
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
563
Antihypertensive Drugs: Action of Diuretics
697
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
697


